Centrexion Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Centrexion Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Centrexion Therapeutics: 12 sponsored US clinical trials, 1 recruiting.
Centrexion Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Nociceptive Pain, with 1 trials.
Top-decile sponsor footprint
Centrexion Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
12 total, page 1 of 1
Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
NCT07122453
Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
NCT04857957
A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects
NCT04154501
An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA
NCT03661996
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
NCT03660943
A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis
NCT03576508
A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain
NCT03429049
A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects
NCT03787004
A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
NCT02678793
Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain
NCT02558439
A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
NCT02283957
Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)
NCT00667654
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Centrexion Therapeutics pipeline
1 recruiting of 12 indexed (8% open); 11 completed (92%).
Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Nociceptive Pain (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Centrexion Therapeutics: open-pipeline peers nationwide
Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Centrexion Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
- Boston VA Research Institute · 8% recruiting · 12 trials
Related
What to do with this Centrexion Therapeutics page
12 registered trials is a research-attention snapshot, not an endorsement of Centrexion Therapeutics or any single study.
- 1 of Centrexion Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Nociceptive Pain is the condition Centrexion Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Nociceptive Pain trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Centrexion Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.